ARVO 2024: Diabetic retinopathy risk factors in paediatric patients with Type 1 diabetes

News
Article

Study results indicate that maintaining control of blood pressure and hemoglobin A1c are key to preventing the onset of diabetic retinopathy

A child has their blood sugar tested using a digital glucometer. Image credit: ©Africa Studio – stock.adobe.com

The study underscored the significant associations seen with older age, longer disease duration, earlier disease onset and some modifiable risk factors. Image credit: ©Africa Studio – stock.adobe.com

A chart review showed that diabetic retinopathy (DR) is associated with older age, longer duration of type 1 diabetes, earlier onset of type 1 diabetes and some modifiable risk factors.

The results, according to first author Konstantina Sampani, MD, indicated that maintaining control of blood pressure (BP) and hemoglobin A1c (HbA1c) are key to preventing the onset of DR. Dr Sampani, who is from the Joslin Diabetes Center Beetham Eye Institute, Boston, Massachusetts, presented the findings of her group at the Association for Research in Vision and Ophthalmology (ARVO) annual meeting in Seattle.

The investigators conducted a retrospective chart review of patients’ demographic and clinical data from 2005 to 2020.

The investigators used spectral-domain optical coherence tomography (SD-OCT) macular scans for a subset of patients and automated retinal layer segmentation to determine the inner and outer layers (IRL, ORL). The researchers sought correlations between the patient demographics, body mass index (BMI), BP, HbA1c, and retinal layer cell thickness and volume with the presence of DR, she recounted.

Key findings

The demographic data from the cohort were as follows. A total of 1,359 patients (2,704 eyes; 49.6% female; mean age, 13.7±4.3 years) were included. The mean duration of the type 1 diabetes was 7.0±5.2 years; the mean age at onset of type 1 diabetes, 7.7±4.7 years; mean HbA1c, 8.4±1.3%; mean BMI, 21.9±4.3; mean systolic BP, 109.2±10.4; and mean diastolic BP, 65.8±7.4.

Of the 2,704 eyes, 139 (5.14%) had DR, of which 5.1% was nonproliferative and 0.04% was proliferative.

The following significant correlations were found with the presence of DR: older age (p<0.001), longer duration of type 1 diabetes (p<0.001), earlier onset of type 1 diabetes (p<0.04), higher HbA1c (p<0.001), and high systolic and diastolic BP (each p<0.001). They also pointed out that these correlations remained significant after adjusting for age, gender, HbA1c, duration of type 1 diabetes and the age at onset of type 1 diabetes.

A subset of 109 eyes (69 patients) who had SD-OCT images and no DR had higher HbA1c values that were associated significantly with thinner central subfield thickness (p = 0.001) and thinner IRL (p=0.004). Higher systolic BP also was correlated significantly with increased IRL volume (p=0.02). No significant relationships were identified between the total IRL or ORL thickness and the BMI, diastolic BP or duration of type 1 diabetes.

The study underscored the significant associations seen with older age, longer disease duration, earlier disease onset and some modifiable risk factors, and the importance of controlling BP and HbA1c to prevent disease onset.

In addition, the correlation between higher HbA1c and thinner IRL in eyes without DR may mean that neurodegeneration is associated with worse glycemic and BP control. The authors emphasised that their results highlight the importance of controlling modifiable risk factors to prevent DR and potentially reduce subclinical neural retinal loss in young patients with type 1 diabetes.

Reference

Sampani K, Keady J, Silva PS, et al. Risk factors for diabetic retinopathy and neural retinal degeneration in youth with type 1 diabetes. Paper presented at the Association for Research in Vision and Ophthalmology annual meeting; May 5-9, 2024, Seattle, WA. Presentation number: 956

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
At the Retina World Congress, Siegfried Priglinger, MD, speaks about ensuring the best outcomes for preschool-aged patients
At the 2025 ASCRS meeting, Robert Ang, MD said small aperture IOLs can benefit all patients, especially those with complex corneas or who have undergone previous corneal refractive surgery
Viha Vig, MBChB graduate student at the University of Auckland, New Zealand, discusses her poster presentation on the relationship between mitochondiral disease, Alzheimer disease, and other types of dementia.
Alfredo Sadun, MD, PhD, chief of Ophthalmology at the Doheny Eye Institute, University of California Los Angeles, shared exciting new research with the Eye Care Network during the Association for Research in Vision and Ophthalmology (ARVO) meeting on the subject of Leber hereditary optic neuropathy (LHON).
At this year's Association for Research in Vision and Ophthalmology (ARVO) meeting in Salt Lake City, Utah, Nitish Mehta, MD, shared highlights from his research documenting real-world results of aflibercept 8 mg for patients with diabetic macular oedema.
ARVO 2025: Anat Loewenstein, MD, shares data from herself and her colleagues on meeting needs of patients with diabetic retinopathy
At the American Society of Cataract and Refractive Surgeons annual meeting, Sheng Lim, MD, FRCOphth discusses the benefit of endoscopic cyclophotocoagulation for patients with primary open angle glaucoma and cataracts in the CONCEPT study
A photo of Seville, Spain, with the Congress on Controversies in Ophthalmology logo superimposed on it. Image credit: ©francovolpato – stock.adobe.com; logo courtesy COPHy
Anat Loewenstein, MD, Professor and Director, Department of Ophthalmology, Tel Aviv Medical Center, discusses the Congress on Controversies in Ophthalmology (COPHy)
Anat Loewenstein, MD, speaks about the 22nd Annual Angiogenesis, Exudation, and Degeneration Meeting in February 2025 and shares her global forecast for AI-driven home OCT
© 2025 MJH Life Sciences

All rights reserved.